A5081506508- PARP inhibition in cancer therapy
- Phytochemicals and Medicinal Plants
- Toxin Mechanisms and Immunotoxins
- Multiple Myeloma Research and Treatments
- Chemokine receptors and signaling
- Tuberous Sclerosis Complex Research
- Phagocytosis and Immune Regulation
- Chronic Myeloid Leukemia Treatments
- 3D Printing in Biomedical Research
- DNA Repair Mechanisms
- Pediatric Hepatobiliary Diseases and Treatments
- MicroRNA in disease regulation
- Inhalation and Respiratory Drug Delivery
- Monoclonal and Polyclonal Antibodies Research
- Multiple and Secondary Primary Cancers
- Protein purification and stability
- Immunotherapy and Immune Responses
- Pharmacogenetics and Drug Metabolism
- Chemical Synthesis and Analysis
- Integrated Circuits and Semiconductor Failure Analysis
- Single-cell and spatial transcriptomics
- Biosimilars and Bioanalytical Methods
- Immunotoxicology and immune responses
- Pancreatitis Pathology and Treatment
- Liver Disease Diagnosis and Treatment
AstraZeneca (United Kingdom)
2017-2024
AstraZeneca (Brazil)
2019
Extracellular vesicles (EVs) mediate cellular communication through the transfer of active biomolecules, raising interest in using them as biological delivery vehicles for therapeutic drugs. For drug applications, it is important to understand intrinsic safety and toxicity liabilities EVs. Nanoparticles, including EVs, typically demonstrate significant accumulation liver after systemic administration vivo. We confirmed uptake EVs derived from Expi293F cells into HepG2 did not detect any...
Abstract Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed selectivity over PARP2, which has been shown play a role in the survival hematopoietic/stem progenitor cells animal models. developed AZD5305 with aim achieving improved clinical efficacy wider therapeutic window. This next-generation PARP inhibitor (PARPi) could provide paradigm shift outcomes achieved by first-generation PARPi,...
Introduction: Microphysiological systems (MPS; organ-on-a-chip) aim to recapitulate the 3D organ microenvironment and improve clinical predictivity relative previous approaches. Though MPS studies provide great promise explore treatment options in a multifactorial manner, they are often very complex. It is therefore important assess manage technical confounding factors, maximise power, efficiency scalability. Methods: As an illustration of how can benefit from systematic evaluation...
caped, and the whole organ was disorganized, absolutely inca- pable of recovery." Water found in consider-
Abstract Current clinical poly (ADP-ribose) polymerase (PARP) inhibitors target both PARP1 and PARP2 they all cause cytopenias with varying severity. Understanding the mechanism underlying hematological toxicity of these agents is key for rational design a best-in-class molecule greater therapeutic potential, as monotherapy in combination chemotherapy. We validated rat physiologically competent translational model to investigate PARP inhibitor-driven toxicity. Here we demonstrate that...
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Data from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Data from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
<div>AbstractPurpose:<p>We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed selectivity over PARP2, which has been shown play a role in the survival hematopoietic/stem progenitor cells animal models. We developed AZD5305 with aim achieving improved clinical efficacy wider therapeutic window. This next-generation PARP inhibitor (PARPi) could provide paradigm shift outcomes achieved by...
<div>AbstractPurpose:<p>We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed selectivity over PARP2, which has been shown play a role in the survival hematopoietic/stem progenitor cells animal models. We developed AZD5305 with aim achieving improved clinical efficacy wider therapeutic window. This next-generation PARP inhibitor (PARPi) could provide paradigm shift outcomes achieved by...
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Data from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Supplementary Data from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper